Official Title
Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus
Brief Summary

Since december 2019, acute respiratory disease due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. There is no confirmed antivirus therapy for 2019-nCoV infection. Natural killer (NK) cells are innate lymphocytes that may serve as useful effectors against danger infection. The purpose of this clinical investigation is to evaluate the safety and efficiency of NK Cells in combination with standard therapy for pneumonia patients infected with 2019-nCoV.

Recruiting
Novel Coronavirus Pneumonia

Biological: NK Cells
twice a week of NK cells (0.1-2*10E7 cells/kg body weight)
NK Cells Treatment Group

Eligibility Criteria

Inclusion Criteria:

- 1. Male or female, aged at 18 years-65 years old

- 2. Pneumonia that is judged by chest radiograph or computed tomography

- 3. Laboratory confirmation of NCP infection by reverse-transcription polymerase chain reaction(RT-PCR) from any diagnostic sampling source

Exclusion Criteria:

- 1. Pregnancy or breastfeeding

- 2. Known HIV, HBV or HCV infection

- 3. Patients with malignant tumor, other serious systemic diseases and psychosis

- 4. Patients who are participating in other clinical trials

- 5. Inability to provide informed consent or to comply with test requirements

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years~Maximum: 65 Years
Countries
China
Contacts

ZHU, Professor
00863733029089
wulingzhu@xxmu.edu.cn

Xinxiang medical university
First Affiliated Hospital of Xinjiang Medical University
NCT Number
MeSH Terms
Coronavirus Infections
Pneumonia